Testing effectiveness (Phase 2)Ended earlyNCT02002689What this trial is testingLDE225 for Patients With PTCH1 or SMO Mutated TumorsWho this might be right forPTCH1 or SMO Activated Solid and Hematologic Tumors Novartis Pharmaceuticals 10